Filtered By:
Source: Journal of the American College of Cardiology

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 269 results found since Jan 2013.

Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction-51)
Objectives: The present analysis reports on the pre-specified subgroup of ST-elevation myocardial infarction (STEMI) patients, in whom anticoagulant therapy has been of particular interest. Background: In ATLAS ACS-2–TIMI-51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction-51), rivaroxaban reduced cardiovascular events across the spectrum of acute coronary syndrome (ACS). Methods: Seven thousand eight hundred seventeen patients in ATLAS ACS-2-TIMI 51 presented with a STEMI. After being stabilized (1 to 7 d...
Source: Journal of the American College of Cardiology - May 1, 2013 Category: Cardiology Authors: Jessica L. Mega, Eugene Braunwald, Sabina A. Murphy, Alexei N. Plotnikov, Paul Burton, Robert Gabor Kiss, Alexander Parkhomenko, Michal Tendera, Petr Widimsky, C. Michael Gibson Tags: Coronary Artery Disease Source Type: research

Comparison of Transcatheter and Surgical Aortic Valve Replacement in Severe Aortic Stenosis: A Longitudinal Study of Echocardiography Parameters in Cohort A of the PARTNER Trial (Placement of Aortic Transcatheter Valves)
This study sought to compare echocardiographic findings in patients with critical aortic stenosis following surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).Background: The PARTNER (Placement of Aortic Transcatheter Valves) trial randomized patients 1:1 to SAVR or TAVR.Methods: Echocardiograms were obtained at baseline, discharge, 30 days, 6 months, 1 year, and 2 years after the procedure and analyzed in a core laboratory. For the analysis of post-implantation variables, the first interpretable study (≤6 months) was used.Results: Both groups showed a decrease in aortic valve grad...
Source: Journal of the American College of Cardiology - April 25, 2013 Category: Cardiology Authors: Rebecca T. Hahn, Philippe Pibarot, William J. Stewart, Neil J. Weissman, Deepika Gopalakrishnan, Martin G. Keane, Saif Anwaruddin, Zuyue Wang, Martin Bilsker, Brian R. Lindman, Howard C. Herrmann, Susheel K. Kodali, Raj Makkar, Vinod H. Thourani, Lars G. Tags: Catheter Versus Surgical Intervention Source Type: research

Reply
We thank Drs. Eleid and Pellikka for their insightful comments with regard to our study and for giving us the opportunity to provide more information in this regard. Paradoxical low-flow, low-gradient (PLF/LG) aortic stenosis (AS) is defined by the constellation of a low-flow state (i.e., stroke volume index ≤35 ml/m2) despite a normal left ventricular (LV) ejection fraction, a small aortic valve area (
Source: Journal of the American College of Cardiology - April 24, 2013 Category: Cardiology Authors: Marie-Annick Clavel, Jean G. Dumesnil, Romain Capoulade, Patrick Mathieu, Mario Sénéchal, Philippe Pibarot Tags: Letters to the Editor Source Type: research

5-Year Experience With Transcatheter Transapical Mitral Valve-in-Valve Implantation for Bioprosthetic Valve Dysfunction
Objectives: The study sought to describe the authors' experience with mitral transapical transcatheter valve-in-valve implantation (TVIV). Background: Increasing numbers of mitral biological prostheses are being implanted in clinical practice. Transcatheter valve-in-valve implantation may be a lower risk alternative treatment for high-risk patients with mitral valve degeneration. Methods: Twenty-three consecutive patients with severe mitral bioprosthetic valve dysfunction underwent transapical mitral TVIV between July 2007 and September 2012. Bioprosthetic failure was secondary to stenosis in 6 (26.1%), regurgitation ...
Source: Journal of the American College of Cardiology - April 24, 2013 Category: Cardiology Authors: Anson Cheung, John G. Webb, Marco Barbanti, Melanie Freeman, Ronald K. Binder, Christopher Thompson, David A. Wood, Jian Ye Tags: Interventional Cardiology Source Type: research

The Relationship Between Metabolic Risk Factors and Incident Cardiovascular Disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited)—A Prospective Population-Based Study
This study sought to determine whether ethnic differences in diabetes, dyslipidemia, and ectopic fat deposition account for ethnic differences in incident cardiovascular disease. Background: Coronary heart disease risks are elevated in South Asians and are lower in African Caribbeans compared with Europeans. These ethnic differences map to lipid patterns and ectopic fat deposition. Methods: Cardiovascular risk factors were assessed in 2,049 Europeans, 1,517 South Asians, and 630 African Caribbeans from 1988 through 1991 (mean age: 52.4 ± 6.9 years). Fatal and nonfatal events were captured over a median 20.5-year follo...
Source: Journal of the American College of Cardiology - April 24, 2013 Category: Cardiology Authors: Therese Tillin, Alun D. Hughes, Jamil Mayet, Peter Whincup, Naveed Sattar, Nita G. Forouhi, Paul M. McKeigue, Nish Chaturvedi Tags: Cardiometabolic Risk Source Type: research

Quality of Life Assessment in the Randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) Trial of Patients at Risk for Stroke With Nonvalvular Atrial Fibrillation
Conclusions: Patients with nonvalvular AF at risk for stroke treated with left atrial appendage closure have favorable QOL changes at 12 months versus patients treated with warfarin. (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation [WATCHMAN PROTECT]; NCT00129545)
Source: Journal of the American College of Cardiology - April 24, 2013 Category: Cardiology Authors: Oluseun Alli, Shepal Doshi, Saibal Kar, Vivek Reddy, Horst Sievert, Chris Mullin, Vijay Swarup, Brian Whisenant, David Holmes Tags: Heart Rhythm Disorders Source Type: research

Invasive Hemodynamic Characteristics of Low Gradient Severe Aortic Stenosis Despite Preserved Ejection Fraction
Conclusions: Occurrence of low gradient severe aortic stenosis despite preserved ejection fraction was confirmed by invasive hemodynamics and was not the result of a systematic bias in the echo calculation of aortic orifice area.
Source: Journal of the American College of Cardiology - April 24, 2013 Category: Cardiology Authors: Juliane Lauten, Christian Rost, Ole A. Breithardt, Christian Seligmann, Lutz Klinghammer, Werner G. Daniel, Frank A. Flachskampf Tags: Heart Valve Disease Source Type: research

Platelet Responsiveness to Clopidogrel Treatment After Peripheral Endovascular Procedures: The PRECLOP Study: Clinical Impact and Optimal Cutoff Value of On-Treatment High Platelet Reactivity
This study aimed to assess the clinical implications and optimal cutoff value of high platelet reactivity (HPR) in patients receiving clopidogrel for peripheral endovascular procedures.Background: As noted in coronary studies, HPR could be related to increased adverse events.Methods: This prospective trial included patients receiving clopidogrel 75 mg daily, before and after infrainguinal angioplasty or stenting. Platelet inhibition was assessed with the VerifyNow P2Y12 point-of-care test. Primary endpoints were 1-year clinical events rate (composite endpoint of death, major stroke, major amputation, target vessel revascul...
Source: Journal of the American College of Cardiology - April 18, 2013 Category: Cardiology Authors: Stavros Spiliopoulos, Georgios Pastromas, Konstantinos Katsanos, Panagiotis Kitrou, Dimitrios Karnabatidis, Dimitrios Siablis Tags: Interventional Cardiology Source Type: research

Primary Percutaneous Coronary Intervention: The Deception of Delay⁎
Primary percutaneous coronary intervention (PCI) has become the predominant reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) throughout western healthcare systems. Recent estimates in the United States suggest that primary PCI is used in 85% of all STEMI cases that undergo reperfusion, with thrombolytic agents used in only 9% and the combination of thrombolytic agents with PCI in 6% (). This dramatic switch from thrombolytic therapy to primary PCI was the result of several studies conducted in the early 1990s that demonstrated the superiority of primary PCI at reducing stroke and reinfarction as ...
Source: Journal of the American College of Cardiology - April 17, 2013 Category: Cardiology Authors: Cindy L. Grines, Theodore Schreiber Tags: Acute Coronary Syndromes: Editorial Comment Source Type: research

Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation: The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)
Conclusions: LAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation. (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578)
Source: Journal of the American College of Cardiology - April 12, 2013 Category: Cardiology Authors: Vivek Y. Reddy, Sven Möbius-Winkler, Marc A. Miller, Petr Neuzil, Gerhard Schuler, Jens Wiebe, Peter Sick, Horst Sievert Tags: Atrial Fibrillation Source Type: research

Antithrombotic Treatment in Transcatheter Aortic Valve Implantation: Insights for Cerebrovascular and Bleeding Events
Transcatheter aortic valve implantation (TAVI) has emerged as a therapeutic alternative for patients with symptomatic aortic stenosis at high or prohibitive surgical risk. However, patients undergoing TAVI are also at high risk for both bleeding and stroke complications, and specific mechanical aspects of the procedure itself can increase the risk of these complications. The mechanisms of periprocedural bleeding complications seem to relate mainly to vascular/access site complications (related to the use of large catheters in a very old and frail elderly population), whereas the pathophysiology of cerebrovascular events re...
Source: Journal of the American College of Cardiology - April 12, 2013 Category: Cardiology Authors: Josep Rodés-Cabau, Harold L. Dauerman, Mauricio G. Cohen, Roxana Mehran, Eric M. Small, Susan S. Smyth, Marco A. Costa, Jessica L. Mega, Michelle L. O'Donoghue, E. Magnus Ohman, Richard C. Becker Tags: STATE-OF-THE-ART PAPER Source Type: research

The Transaortic Approach for Transcatheter Aortic Valve Replacement: Initial Clinical Experience in the United States
Conclusions: TAVR via the TAO approach is technically feasible, seems to be associated with favorable outcomes, and expands the current alternative options for access sites in patients with inoperable aortic stenosis who are ineligible for TF TAVR.
Source: Journal of the American College of Cardiology - April 12, 2013 Category: Cardiology Authors: Joel A. Lardizabal, Brian P. O'Neill, Harit V. Desai, Conrad J. Macon, Alexis P. Rodriguez, Claudia A. Martinez, Carlos E. Alfonso, Martin S. Bilsker, Roger G. Carillo, Mauricio G. Cohen, Alan W. Heldman, William W. O'Neill, Donald B. Williams Tags: Interventional Cardiology Source Type: research

Relationship of Sedentary Behavior and Physical Activity to Incident Cardiovascular Disease: Results From the Women's Health Initiative
Objectives: The aim of this study was to examine the independent and joint associations of sitting time and physical activity with risk of incident cardiovascular disease (CVD).Background: Sedentary behavior is recognized as a distinct construct beyond lack of leisure-time physical activity, but limited data exist on the interrelationship between these 2 components of energy balance.Methods: Participants in the prospective Women’s Health Initiative Observational Study (n = 71,018), 50 to 79 years of age and free of CVD at baseline (1993 to 1998), provided information on sedentary behavior, defined as hours of sitting/d...
Source: Journal of the American College of Cardiology - April 12, 2013 Category: Cardiology Authors: Andrea K. Chomistek, JoAnn E. Manson, Marcia L. Stefanick, Bing Lu, Megan Sands-Lincoln, Scott B. Going, Lorena Garcia, Matthew A. Allison, Stacy T. Sims, Michael J. LaMonte, Karen C. Johnson, Charles B. Eaton Tags: Cardiovascular Risk Source Type: research

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)
This study sought to assess the prognostic value of N-terminal pro–B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.Background: Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases.Methods: In the ARISTOTLE trial, 18,201 patients with AF were randomized to apixaban or warfarin. Plasma samples at randomization were available from 14,892 patients. The association bet...
Source: Journal of the American College of Cardiology - April 5, 2013 Category: Cardiology Authors: Ziad Hijazi, Lars Wallentin, Agneta Siegbahn, Ulrika Andersson, Christina Christersson, Justin Ezekowitz, Bernard J. Gersh, Michael Hanna, Stefan Hohnloser, John Horowitz, Kurt Huber, Elaine M. Hylek, Renato D. Lopes, John J.V. McMurray, Christopher B. Gr Tags: Atrial Fibrillation Source Type: research

Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation: A Prospective Nationwide Cohort Study
Conclusions: In this “everyday clinical practice” post-approval nationwide clinical cohort, there were similar stroke/systemic embolism and major bleeding rates with dabigatran (both doses) compared with warfarin. Mortality, intracranial bleeding, pulmonary embolism, and MI were lower with dabigatran, compared with warfarin. We found no evidence of an excess of bleeding events or MI among dabigatran-treated patients in this propensity-matched comparison against warfarin, even in the subgroup with ≥1-year follow-up.
Source: Journal of the American College of Cardiology - April 4, 2013 Category: Cardiology Authors: Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, Flemming Skjøth, Karen Margrete Due, Torbjörn Callréus, Mary Rosenzweig, Gregory Y.H. Lip Tags: Atrial Fibrillation Source Type: research